Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2024)
44 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 28, 2024
Slide 1: News Release: 2024 Annual Shareholders' Meeting Speech and Presentation
News Release STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) 2024 Annual Shareholders’ Meeting Speech and Presentation Auckland, New Zealand, 28 August 2024 – Fisher & Paykel Healthcare Corporation Limited has provided the attached Chair’s speech and CEO’s slide presentation for the 2024
Slide 2: Chair's Address by Scott St John
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED ANNUAL SHAREHOLDERS’ MEETING 28 AUGUST 2024 ADDRESS BY SCOTT ST JOHN CHAIR I’d like to begin my address by thanking our people, our customers and our clinical partners. Approximately 20 million patients were treated with Fisher & Paykel Healthcare produ
Slide 3: Chair's Address (continued)
steady margin gains prior to the distortion we saw through the pandemic. We are determined to achieve this recovery in a way that does not divert resources in the near term, nor compromise our long-term growth aspirations. This is a balancing act, and I am pleased with our progress so far. The Board
Slide 4: Chair's Address (continued): Board succession
Mark’s appointment will bring the Board up to full strength given my departure. As indicated back in March this year, I am retiring from the Board of Fisher & Paykel Healthcare at the close of this meeting. The highly capable Neville Mitchell has been elected by the Board to become chair. Neville ha
Slide 5: Annual Shareholders' Meeting 28 August 2024
: “4 asnye yosJad 104 HEALTHCARE Fisher & Annual Shareholders’ Meeting 28 August 2024
Slide 6: Online help: virtual meeting
For personal use only Online Help LIVE Virtual Meeting Notice of meeting Annu Fisher &Paykel HEALTHCARE
Slide 7: Your Board
For personal use only Your Board Scott St John % Lisa McIntyre HOHE Lewis Gradon Sir Michael Daniell Pip Greenwood */ y Graham McLean Neville Mitchell Cather Simpson Fisher&.Paykel HEALTHCARE
Slide 8: Agenda
For personal use only Agenda Chair’s Address and Board Subcommittee Updates Managing Director and Chief Executive Officer’s Address Financial Statements Resolutions Voting General Questions Fisher & Paykel HEALTHCARE
Slide 9: Scott St John, Board Chair
For personal use only Scott St John Board Chair Fisher&.Paykel HEALTHCARE
Slide 10: Constant currency growth rates for revenue and net profit after tax
For personal use only Constant currency growth rates for revenue and net profit after tax
Slide 11: Hospital product group
• For personal use only • • *New applications = Noninvasive ventilation (NIV), nasal high flow, surgical
Slide 12: Homecare product group
For personal use only Homecare product group 4M 7.3M 65.6M | 69.56 | 555.80 | $652.3M | Fisher & Paykel HEALTHCARE
Slide 13: Scott St John, Board Chair
For personal use only Scott St John Board Chair Fisher&.Paykel HEALTHCARE
Slide 14: Dividend history
For personal use only • • DIVIDEND HISTORY
Slide 15: Expanding our global reach
Expanding our global reach For personal use only September 2023: We held the official opening ceremony for our third building in Tijuana, Mexico. July 2024: Our team in Guangzhou, China with the first Airvo 2 off the manufacturing line. S N Fisher&.Paykel HEALTHCARE
Slide 16: Environmental and social responsibility
_For personal use only Environmental and social responsibility 12 Fisher&.Paykel HEALTHCARE
Slide 17: Your Board
For personal use only Your Board Scott St John % Lisa McIntyre 13 HOHE Lewis Gradon Sir Michael Daniell Pip Greenwood */ y Graham McLean Neville Mitchell Cather Simpson Fisher&.Paykel HEALTHCARE
Slide 18: Appointment of Mark Cross
For personal use only Appointment of Mark Cross 14 Effective 1 October 2024 Will chair the Audit & Risk Committee with Neville’s move to Board Chair Fisher&.Paykel HEALTHCARE
Slide 19: Scott St John, Board Chair
For personal use only Scott St John 15 Board Chair Fisher&.Paykel HEALTHCARE
Slide 20: Neville Mitchell
For personal use only Neville Mitchell Audit & Risk Committee Chair Incoming Board Chair 6 Fisher & Paykel HEALTHCARE
Slide 21: Lisa McIntyre
For personal use only Lisa McIntyre 7 People & Remuneration Committee Chair Fisher&.Paykel HEALTHCARE
Slide 22: Sir Michael Daniell
For personal use only Sir Michael Daniell 18 Quality, Safety & Regulatory Committee Chair Fisher&.Paykel HEALTHCARE
Slide 23: Lewis Gradon, Managing Director and CEO
For personal use only Lewis Gradon 19 Managing Director and CEO Fisher&.Paykel HEALTHCARE
Slide 24: For personal use only
For personal use only • • • • • • • •
Slide 25: FY25 full year outlook - revenue
FY25 full year outlook - revenue At 31 July exchange rates*, the company expects: * Operating revenue to be in the range of approximately $1.9 billion to $2.0 billion. Hospital contributors * Changing clinical practice * New product introductions *« Northern Hemisphere seasonal hospitalisation rates
Slide 26: New product introductions
For personal use only New product introductions HOSPITAL HOMECARE The F&P 950™ System launched into the US in H1 FY25. F&P Solo™ mask launched into NZ, Australia, Canada and certain European countries in H2 FY 24, followed by the US in H1 FY25. F&P Airvo 3™ nasal high flow device launched into the U
Slide 27: FY25 full year outlook - net profit after tax
For personal use only FY25 full year outlook - net profit after tax At 31 July exchange rates*, the company expects: . thi * Full year net profit after tax to be in the range of Underlying NPAT* history approximately $320 million to $370 million. $524.2M Impacted by: * Revenue (as discussed on the p
Slide 28: Long term gross margin and operating margin targets
70% 40% For personal use only 60% 35% 30% 50% 25% 40% 20% 30% 15% 20% 10% 10% 5% 0% 0% FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24* FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24* Long Term Gross Margin target Long Term Operating Margin target
Slide 29: Continuous improvement at F&P
Continuous improvement at F&P Continuous improvement is embedded across business ='functions and regions, Cc . ro) contributing to our growth. {<) W Global number of Cl S suggestions FY24: £7000 & Global number of Cl __ initiatives executed FY24: ZA170 25
Slide 30: Applications outside of invasive ventilation
For personal use only Invasive Noninvasive Hospital Obstructive Sleep Home Respiratory Respiratory Support Anesthesia Apnea Support Ventilation Ventilation Infant Care Surgical Applications outside of invasive ventilation
Slide 31: Long-term growth aspirations
For personal use only The image above is an illustration of the company’s long-term growth aspirations. It is not a graph and should not be interpreted as being indicative of levels of revenue or profitability in the short term.
Slide 32: Lewis Gradon, Managing Director and CEO
For personal use only Lewis Gradon 28 Managing Director and CEO Fisher&.Paykel HEALTHCARE
Slide 33: Scott St John, Board Chair
For personal use only Scott St John 29 Board Chair Fisher&.Paykel HEALTHCARE
Slide 34: Financial statements
For personal use only Financial statements * Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2024 annual report. ¢ There will be an opportunity to ask any general questions once all items on the agenda have been consid
Slide 35: Resolutions
For personal use only Resolutions NO = ON Ww Re-election of Sir Michael Daniell Election of Graham McLean Auditor’s Remuneration Issue of Performance Share Rights Issue of Options Fisher & Paykel HEALTHCARE
Slide 36: Voting box and Question box
For personal use only Voting box Question box
Slide 37: Resolution 1: Re-election of Sir Michael Daniell
Resolution 1: Re-election of Sir Michael Daniell That Sir Michael Daniell, who retires by > rotation and, being eligible, offers himself 5 for re-election, be re-elected as a director Y of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200
Slide 38: Resolution 2: Election of Graham McLean
Resolution 2: Election of Graham McLean That Graham McLean, who being eligible, offers himself for election, be elected as a 5 director of the Company. 34 Fisher & Paykel Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 For personal use HEALTHCAR
Slide 39: Graham McLean, Director
For personal use only Graham McLean 35 Director Fisher & Paykel HEALTHCARE
Slide 40: Resolution 3: Auditor's Remuneration
Resolution 3: Auditor’s Remuneration That the Directors be authorised to fix the > fees and expenses of PwC as the 5 Company’s auditor. Click “Submit Vote” to lodge your vote. Need help? Call the Link Market Services helpline 0800 200 220 36 Fisher & Paykel HEALTHCARE For personal use
Slide 41: Resolution 4: Issue of Performance Share Rights
Resolution 4: Issue of Performance Share Rights That approval be given for the issue of up >to 100,000 performance share rights 5 under the Fisher & Paykel Healthcare 2022 ® Performance Share Rights Plan to S > Lewis Gradon, Managing Director and a c Chief Executive Officer of the Company. Click “Su
Slide 42: Resolution 5: Issue of Options
Resolution 5: Issue of Options That approval be given for the issue of up > to 190,000 options under the 5 Fisher & Paykel Healthcare 2022 Share g Option Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Click “Submit Vote” to lodge your vote. Need help? Call the Li
Slide 43: For personal use only
Ajuo asn seuossed 104 ykel HEALTHCARE Fisher &Par 39
Slide 44: Thank you for attending today's Annual Shareholders' Meeting
Thank you for attending today’s Annual Shareholders’ Meeting 4 Fisher & Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (August 2024) on 6ix